Skip to main content

Table 2 Bile acid assay of derivation cohort and normal controls

From: Development and validation of bile acid profile-based scoring system for identification of biliary atresia: a prospective study

 

BA (n = 34)

Non-BA (n = 32)

Control (n = 37)

Pa

CA (ng/ml)

9 (8, 13)c

10.3 (8, 15)d

97 (60, 172)

< 0.001

CDCA (ng/ml)

16 (1, 21) b, c

26 (14, 37)d

216 (108, 324)

< 0.001

GDCA (ng/ml)

5.2 (2.0, 7.2)c

1.8 (2.0, 5.9)

0.9 (0.5, 2.9)

< 0.001

GCA (ng/ml)

6160 (3476, 9978) b, c

3044 (1274, 5920)d

820 (428, 1824)

< 0.001

GCDCA (ng/ml)

11,440 (7800, 18,600)b, c

5680 (3474, 10,960)d

2527 (1768, 3980)

< 0.001

TCA (ng/ml)

7936 (4740, 12,245)c

6080 (4080, 10,170)d

574 (249, 1684)

< 0.001

TCDCA (ng/ml)

16,160 (8720, 23,908)c

13,680 (8740, 19,600)d

1633 (784, 3892)

< 0.001

GCDCA/CDCA

685 (394, 1288)b,c

266 (100, 596)d

13 (6, 20)

< 0.001

  1. Data are presented as median (IQR)
  2. a P value: data were analyzed using Kruskal-Wallis test
  3. b Paired comparisons with significance (p < 0.017), using Mann-Whitney test between BA vs Non-BA
  4. c Paired comparisons with significance (p < 0.017), using Mann-Whitney test between BA vs Control
  5. d Paired comparisons with significance (p < 0.017), using Mann-Whitney test between Non-BA vs Control
  6. CA Cholic acid; CDCA Chenodeoxycholic acid; GDCA Glycodeoxycholic acid; GCA Glycocholic acid; GCDCA Glycochenodeoxycholic acid; TCA Taurocholic acid; TCDCA taurochenodeoxycholic acid